Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (271-280 of 442) with videos related to

Pageof 45
Sort By:
Australian Prescriber|May 13, 2024
Assessing, communicating and managing cardiovascular disease risk: a practical summary of the 2023 guidelineGarry Jennings, Natalie Raffoul, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2009
Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIVGeorge Panos, Lavanta Farouk, Justin Stebbing, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Blood|January 4, 2008
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphomaMark Bower, Justin Stebbing, Mark Tuthill, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 11, 2017
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsMark Nelson, Rafael Rubio, Adriano Lazzarin, et al.
Heart, Lung & Circulation|May 31, 2018
Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-StudySi Si, Jonathan Golledge, Paul Norman, et al.
BMC Health Services Research|January 3, 2025
Evaluation of health-related quality of life changes in an Australian rapid access chest pain clinicJ Andrew Black, James E Sharman, Gang Chen, et al.
AIDS (London, England)|October 18, 2005
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapyChristopher M Mela, Catherine T Burton, Nesrina Imami, et al.
Cardiovascular Therapeutics|August 20, 2009
Drug treatment and cost of cardiovascular disease in AustraliaZanfina Ademi, Danny Liew, Derek Chew, et al.
Pageof 45

Showing results (271-280 of 442) with videos related to

Sort By:
Pageof 45
Australian Prescriber|May 13, 2024
Assessing, communicating and managing cardiovascular disease risk: a practical summary of the 2023 guidelineGarry Jennings, Natalie Raffoul, Mark Nelson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2009
Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIVGeorge Panos, Lavanta Farouk, Justin Stebbing, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Blood|January 4, 2008
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphomaMark Bower, Justin Stebbing, Mark Tuthill, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 11, 2017
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsMark Nelson, Rafael Rubio, Adriano Lazzarin, et al.
Heart, Lung & Circulation|May 31, 2018
Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-StudySi Si, Jonathan Golledge, Paul Norman, et al.
BMC Health Services Research|January 3, 2025
Evaluation of health-related quality of life changes in an Australian rapid access chest pain clinicJ Andrew Black, James E Sharman, Gang Chen, et al.
AIDS (London, England)|October 18, 2005
Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapyChristopher M Mela, Catherine T Burton, Nesrina Imami, et al.
Cardiovascular Therapeutics|August 20, 2009
Drug treatment and cost of cardiovascular disease in AustraliaZanfina Ademi, Danny Liew, Derek Chew, et al.
Pageof 45